Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study
Abstract
BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralises interleukin-17A, a cornerstone cytokine in psoriasis, has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations. OBJECTIVE: To report the long-term (2.5-year) efficacy and safety of secukinumab in nail psoriasis.
METHODS: TRANSFIGURE, a double-blind, randomised, placebo-controlled, parallel-group, multicentre Phase 3b study in 198 patients, investigated secukinumab 150 and 300 mg in moderate to severe nail psoriasis patients. RESULTS: At Week 16, the primary endpoint NAil Psoriasis Severity Index (NAPSI) was met, demonstrating superiority of secukinumab to placebo.
The effect was sustained over 2.5 years with a large benefit on nail clearance with mean NAPSI improvement of -73.3% and -63.6% with secukinumab 300 and 150 mg, respectively. At 2.5 years, secukinumab demonstrated sustained clinically significant reductions in total mean Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) QoL scores by -52.4% and -18.1%, and 70.2% and 70.9% of patients achieved a weighted NAPPA-PBI (Patient Benefit Index) global score of >=2 with secukinumab 300 and 150 mg, respectively.
Patients showed considerable improvements in Euro-QoL 5-Dimension Health Status Questionnaire at 2.5 years, reporting decreased pain and discomfort. No new safety findings were observed.
CONCLUSIONS: Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2.5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile.